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Abstract. The present study aimed to elucidate the clini-
copathological characteristics of resected mucinous cystic 
neoplasm (MCN) with ovarian-type stroma and identify a 
surgical approach for MCN treatment, on the basis of Republic 
of Korean (Yonsei University College of Medicine, Seoul, 
South Korea) and Japanese (Nippon Medical School, Tokyo, 
Japan) bi-institutional collaboration. The present study retro-
spectively reviewed 55 MCNs with ovarian-type stroma using 
pathological re-examination. Clinicopathological features and 
preoperative clinical parameters were evaluated to predict 
malignant alterations in MCNs. The proportion of surgically 
treated MCNs has recently been increasing. All patients 
included in the present study were female, with a mean age 
of 47.9±13.3 years. Mural nodules were noted in 8 patients 
(14.5%) and the mean cyst size was 6.1±4.2 cm. A total of 
9 patients (16.4%) were identified to exhibit non-invasive 
mucinous cystadenocarcinoma. The number of patients with 
small tumors (R2=-0.079, P=0.038) and asymptomatic pancre-
atic MCNs (P=0.022) was significantly increased (P<0.05), 
which resulted in the more frequent application of minimally 
invasive surgery (P<0.001). During the follow‑up period 
(mean, 51.6 months; range, 1.1-242.8 months), no recurrence 
or tumor‑associated mortality was identified. The presence of 
mural nodules (P=0.002) and a tumor size ≥4.5 cm (P=0.027) 
were identified as potential clinical parameters for predicting 
malignant transformation. The significance of mural nodules 
in predicting malignant transformation was increased in large 
MCNs (≥4.5 cm) of the pancreas compared with small MCNs 
(<4.5 cm) (P=0.002). Overall, non‑invasive pancreatic MCNs 
are not aggressive, and minimally invasive pancreatectomy 
may be an effective approach for suitable patients.
Introduction
With improvements in socioeconomic conditions, individuals 
have developed an increased concern for their personal health. 
As a result, routine medical check-ups and use of highly avail-
able imaging procedures have led to the increased diagnosis 
of asymptomatic pancreatic cystic lesions worldwide (1). A 
cystic tumor of the pancreas is pathologically heterogeneous 
and accounts for between 10 and 15% of cystic lesions of the 
pancreas (2). Pancreatic cystic tumors are biologically diverse 
and typically categorized as a serous cystic neoplasm (SCN), 
a mucinous cystic neoplasm (MCN), an intraductal papillary 
mucinous neoplasm (IPMN) or a solid pseudopapillary tumor 
of the pancreas (SPT). MCN of the pancreas is a notable 
pathological entity of the pancreas, histologically composed 
of inner epithelial mucin-secreting cells and a surrounding 
dense ovarian-type stroma. However, there has been confu-
sion between MCN and IPMN, as ovarian-type stroma was 
not previously regarded as a diagnostic criterion for MCN (3). 
However, the World Health Organization classification in 
2000 emphasized the significance of ovarian stroma for the 
diagnosis of MCNs (4,5) and the consensus meeting of the 
International Association of Pancreatology, held in Sendai 
Japan, restricted the term MCN to a neoplasm with the pres-
ence of ovarian stroma (6).
According to a Korean multi-institutional survey (7), 
MCN was identified to be the second most common type 
of neoplastic cyst of the pancreas in Korea. The majority of 
MCNs are identified in middle‑aged females, and are typically 
located in the body and tail of the pancreas (8-10). MCNs have 
been demonstrated to exhibit malignant potential, but a good 
prognosis. However, the diagnosis of pancreatic MCN remains 
rare, comprising between 1 and 2% all pancreatic tumors (11). 
Surgical experience of 163 resected MCNs was previously 
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analyzed by one study (12), however, only a limited number of 
other studies have described surgical experiences with MCNs.
In the present study, surgical experience with MCN of 
the pancreas was reviewed, on the basis of Korean (Yonsei 
University College of Medicine; YUCM) and Japanese 
(Nippon Medical School; NMS) bi-institutional collaboration. 
In addition, the present study aimed to identify the clinico-
pathological characteristics of pancreatic MCNs detected 
between January 1990 and December 2012. Furthermore, 
the pre-surgical clinical parameters that are predictive of 
malignant transformation were analyzed to identify effective 
surgical management of MCN of the pancreas.
Materials and methods
Patients. Between January 1990 and December 2012, 
68 patients (YUCM, 45 patients; NMS, 23 patients) under-
went pancreatectomy for non-invasive MCN of the pancreas. 
Among patients who underwent surgical resection of known 
MCN, cases that exhibited MCNs were reviewed. A total of 55 
out of 68 cases, those that exhibited mucin-secreting epithelial 
cells and a dense ovarian stroma, were selected for the present 
study. All patients included in the present study were female, 
with a mean age of 47.9±13.3 years (range, 24-75 years). All 
patients were diagnosed and classified using the International 
Agency for Research on Cancer/World Health Organization 
2010 classification (13).
Medical records review. The available medical records were 
reviewed to identify the general characteristics, clinical 
presentations, surgical outcomes and pathological results 
of the patients. Chronological alterations in MCNs of the 
pancreas were analyzed and grouped as follows: Period 1, 
between January 1990 and December 1999; period 2, between 
January 2000 and December 2006; and period 3, between 
January 2007 and December 2012. In addition, patients 
were divided into the following two groups: The minimally 
invasive approach group (MIS), for those who underwent 
laparoscopic or robot-assisted surgery; and the open surgery 
group (conventional). Subsequently, clinicopathological 
characteristics of MCNs and perioperative outcomes were 
reviewed. A postoperative pancreatic fistula (POPF) was 
defined according to the guidelines of the International Study 
Group on Pancreatic Fistulas (ISGPF) (14). Furthermore, 
postoperative bleeding was defined by the criteria proposed 
by the ISGPF (15). Mortality was defined as mortality within 
30 days of surgery whether in or outside of the hospital. 
Follow‑up data was reviewed for recurrence or tumor‑specific 
mortality.
Statistical analysis. Categorical variables were presented as 
frequency and percentage, and continuous variables as the 
mean ± standard deviation. A receiver operating characteristic 
curve was used to estimate the optimal tumor size and predict 
the malignant transformation of MCN of the pancreas. The 
χ2 test (Fisher's exact test), Mann-Whitney test and linear 
regression analysis were used for statistical assessment of 
associations. P<0.05 was considered to indicate a statistically 
significant difference. All statistical analyses were performed 
using IBM SPSS v.22.0 (IBM Corp., Armonk, NY, USA).
Results
Patient characteristics. For the 68 patients, 13 pathological 
specimens (13/68, 19.1%) were revealed not to be MCNs 
(10/13, IPMNs; 3/13, pancreatic intraepithelial neoplasia 
cases). Excluding the 13 patients, a total of 55 patients with 
non-invasive MCN of the pancreas were analyzed. All patients 
were female, with a mean age of 47.9±13.3 years. A total of 
19 patients (19/55, 34.5%) were identified to exhibit a pancre-
atic cystic tumor via routine medical check-up. Abdominal 
discomfort (15/55, 27.3%) was the most common clinical 
symptom. General weakness and weight loss was demon-
strated in 9 patients (16.4%) and an abdominal mass was 
identified in 3 patients (5.5%). Diabetes mellitus was demon-
strated in 4 patients (7.3%) and 6 patients (10.9%) exhibited 
an extra-pancreatic malignant disease, including breast cancer 
in 2 patients, cervical cancer in 1 patient, thyroid cancer in 1 
patient, hepatocellular carcinoma in 1 patient and early gastric 
cancer in 1 patient.
Preoperative imaging study. All patients received abdominal 
computed tomography, whereas abdominal endoscopic 
ultrasound scans, magnetic resonance imaging and endo-
scopic retrograde cholangiopancreatography were selectively 
performed for preoperative evaluation to characterize cystic 
tumors if mural nodules appeared in a preoperative computed 
tomography scan. There was no definitive radiological evidence 
of local invasiveness in all patients, but 8 patients (8/55, 14.5%) 
exhibited an intracystic solid component (mural nodule). The 
mean size of the surgical specimen was 6.1±4.2 cm and the 
majority of cystic tumors (52/55, 94.5%) were located in the 
distal pancreas (body and tail of the pancreas), with only 3 
(3/55, 5.5%) in the pancreatic head.
Selection of surgical procedures. It was demonstrated that 
distal pancreatectomy with or without splenectomy was the 
most common type of surgical procedure for treating MCN of 
the pancreas (46/55, 83.6%). Cyst enucleation was performed 
in 5 patients (5/55, 9.1%), and pancreatoduodenectomy was 
performed in 3 patients (3/55, 5.5%). A laparoscopic or 
robot-assisted minimally invasive approach was applied in 
31 patients (31/55, 56.4%). When considering cases of distal 
pancreatectomy, there were significant different clinical char-
acteristics between the two institutions (Table I). In NMS, 
the minimally invasive surgical approach was performed 
more frequently compared with the conventional surgical 
approach (P=0.005). However, the spleen-preserving proce-
dure was more frequent in YUCM (P=0.069). Comparing the 
data from the two institutions, tumor size was demonstrated 
to be similar; however, tumor location and associated symp-
toms were identified to be significantly different (P<0.05; 
Table I).
Postoperative outcomes. There was no postoperative mortality. 
A POPF was developed in 10 patients (10/55, 18.2%; grade B, 
n=9; and grade C, n=1) and postoperative hemorrhage was 
identified in 1 patient (1/55, 1.8%). MCN-adenoma was identi-
fied in 15 patients (27.3%) and MCN‑borderline in 20 patients 
(36.4%). Focal non-invasive carcinoma was identified in 
9 patients (9/55, 16.4%).
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Chronological alterations in surgically resected MCNs of the 
pancreas. A total of 11 patients (20%) were surgically treated 
for MCN of the pancreas in period 1, 16 patients (29.1%) in 
period 2 and 28 patients (50.9%) in period 3. The number 
of treated patients per year in period 3 increased by 5-fold 
compared with those in period 1 (Fig. 1). Tumor size generally 
decreased over all periods. (Fig. 2) [tumor size=(-0.072) x case 
sequence (order of operation) + 8.088; P=0.038]. Therefore, 
asymptomatic patients were more frequently found through 
routine medical check-up (P=0.022), and minimally invasive 
surgery, such as the laparoscopic and robot-assisted approach, 
was frequently applied in the recent surgical period (P<0.001). 
Furthermore, a significant increase was demonstrated in 
spleen-preserving surgery, when performing distal pancre-
atectomy, between periods (P=0.026; Table II).
Comparative analysis between conventional and minimally 
invasive surgical approaches. A total of 31 patients (56.4%) 
underwent minimally invasive pancreatectomy for MCN 
of the pancreas. Conventional laparoscopic approach was 
performed in 26 patients (26/55, 47.3%) and robot-assisted 
distal pancreatectomy was conducted in 5 patients (5/55, 
9.1%). Compared with the conventional group, the MIS 
group demonstrated an increased number of asymptomatic 
patients (P=0.059), a smaller tumor size (radiological size, 
7.4±5.32 vs. 4.9±2.8 cm, P=0.045; pathological size, 7.3±5.9 
vs. 4.6±2.1 cm, P=0.044) and an increased surgical dura-
tion (208.3±95.4 vs. 316.3±152.1 min, P=0.004). Notably, 
hospital stay was similar between the two groups (12.7±6.7 
vs. 13.8±9.6 days, P=0.412). However, it was demonstrated 
that the post-surgical hospital stay was distinct between the 
Table II. Alterations in the clinical characteristics of pancreatic 
mucinous cystic neoplasms, according to the time of surgery.
 Period
 ---------------------------------------------------------
Characteristic 1 2 3 P-value
Age, yearsa 47.3±14.3 51.1±10.9 46.5±14.4 0.545
Sex    0.545
  Male 0 0 0 
  Female 11 16 28 
Symptoms    0.022
  No 2 12 19 
  Yes 9 4 9 
Tumor size, cma 8.0±6.4 6.2±3.8 5.2±3.0 0.250
Malignant    0.113
transformation
  No 9 11 26 
  Yes 2 5 2 
Surgery    <0.001
  Conventional 11 10 3 
  Minimally invasive - 6 25 
Spleen-preservinga,b    0.026
  No  5 13 19 
  Yes 0 0 9 
aMean ± standard deviation. bConsidering distal pancreatectomy 
only. Period 1, January 1991‑December 1991; period 2, January 
2000‑December 2006; period 3, January 2007‑December 2012. 
Conventional, open surgery; minimally invasive, laparoscopic or 
robot-assisted surgery.
Table I. Clinical characteristics of distal pancreatectomy in 
two institutions.
Characteristic YUCM (n=28) NMS (n=18) P-value
Age, yearsa 46.3±12.3 51.1±14.1 0.839
Sex
  Female 28 18 
  Male 0 0 
Symptoms   0.003
  No 14 15 
  Yes 14 3 
R-Tumor sizea 6.5±4.2 5.7±3.4 0.068
Spleen-preserving   0.069
  No 20 17 
  Yes 8 1 
Tumor location   <0.001
  Body 13 6 
  Tail 15 4 
  Body+tail - 8 
Surgery   0.005
  Conventional 15 2 
  Laparoscopic 13 16 
LOH, daysa,b 8.1±4.2 19.2±10.2 <0.001
aMean ± standard deviation. bConsidering laparoscopic approach only. 
LOH, length of postoperative hospital stay considering laparoscopic 
approach only; YUCM, Yonsei University College of Medicine; 
NMS, Nippon Medical School; R-tumor size, tumor size determined 
by radiologist.
Figure 1. Number of surgically treated patients with mucinous cystic 
neoplasms according to three different time periods.
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two groups when considering individual institutional analysis 
(YUCM, 12.4±6.9 vs. 8.1±4.2 days, P=0.045; NMS, 16.5±2.1 
vs. 19.2±10.2 days, P=0.394) (Table III).
Preoperative prediction of malignant transformation. 
Malignant transformation (focal non-invasive mucinous cyst-
adenocarcinoma) was observed in 9 patients (9/55, 16.4%). 
Follow-up data was available for 51 patients (51/55, 92.7%) and 
4 patients were lost to follow-up. The mean follow-up duration 
was 51.6 months (range, 1.1-242.8 months). Neither recur-
rence nor tumor-associated mortality was observed in benign, 
borderline MCNs or MCNs with malignant transformation. 
A tumor size of >4.5 cm was identified to predict malignant 
transformation of MCN with an 88.9% sensitivity and a 45.7% 
false-positive rate (1-specificity), and this threshold value 
was statistically significant in the preoperative prediction of 
malignant transformation [area under the curve (AUC), 0.719; 
P=0.039; Fig. 3]. Radiological tumor size (≥4.5 cm; P=0.027) 
and intra-cystic solid portions (mural nodule; P=0.002) were 
identified as important preoperative clinical parameters to 
predict malignant transformation (Table IV). In particular, 
the significance of mural nodules in predicting malignant 
transformation was significant in large MCNs of the pancreas 
(≥4.5 cm; P=0.002; Table V).
Discussion
Pancreatic cancer is known to be one of the most lethal 
gastrointestinal malignant diseases. Overall survival is <5% 
and complete surgical resection is the most effective treat-
ment approach (16). However, between 10 and 15% of patients 
with pancreatic cancer may be surgical candidates and the 
long-term survival rate is between 10 and 20% with surgical 
resection (17-19). Therefore, early detection and prevention 
are critical to improve the outcome of pancreatic cancer. 
MCN of the pancreas is potentially malignant and previous 
studies have suggested the presence of adenoma-carcinoma 
sequences (9,20,21). Although the outcome of mucinous 
cystadenocarcinoma is known to be superior to that of 
ductal adenocarcinoma of the pancreas (22,23), the 5-year 
disease‑specific survival rate for patients with invasive muci-
nous cystadenocarcinoma is ~30% (10). Therefore, complete 
resection of the tumor prior to the development of invasive 
cancer is considered an important surgical goal in treating 
MCNs of the pancreas.
Pancreatic MCN is not an aggressive cancer (12,24). As 
described in the present study, in the follow-up of patients 
available (mean, 51.6 months (range, 1.1-242.8 months), neither 
recurrence nor tumor-specific mortality was observed in all 
MCNs with malignant transformation. Therefore, pancreatic 
surgeons should consider a patient's quality of life following 
Table III. Comparative analysis between conventional open 
and minimally invasive surgical approaches.
  Minimally
Feature Conventional invasive P-value
Age, yearsa 48.1±12.9 48.1±14.4 0.773
Sex   
  Male 0 0 
  Female 24 31 
Symptom   0.059
  No 11 22 
  Yes 13 9 
R tumor size, cma 7.4±5.2 4.9±2.8 0.045
P tumor size, cma 7.3±5.9 4.6±2.1 0.044
Location   0.077
  Proximal 3 - 
  Distal 21 31 
Type of resection   
  EN 3 2 
  SpDP 1 8 
  DPS 16 21 
  PD 3 ‑ 
  CP 1 - 
Surgical duration, mina  208.3±95.4 316.3±152.1 0.004
Bleeding amount, mla 726.8±211 331.6±426.3 0.059
Transfusion   0.863
  No 22 28 
  Yes 2 3 
POPF Grade B   0.336
No 21 24 
Yes 3 7 
LOH, days 12.7±6.7 13.8±9.6 0.079
YUCM 12.4±6.9   8.1±4.2 0.45
NMS 16.5±2.1   19.2±10.2 0.941
aMean ± standard deviation. MIS, minimally invasive surgery; EN, 
enucleation; SpDP, spleen‑preserving distal pancreatectomy; DPS, 
distal pancreatosplenectomy; PD, pancreaticoduodenectomy; CP, 
central pancreatectomy; LOH, length of hospital stay; R, tumor size 
measured by radiologist; P, tumor size measured by pathologist; 
POPF, postoperative pancreatic fistula; YUCM, Yonsei University 
College of Medicine; NMS, Nippon Medical School.
Figure 2. Correlation between order of surgical procedures and tumor size of 
pancreatic mucinous cystic neoplasm (R2=-0.079, P=0.038).
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pancreatectomy, as long-term survival is expected only if surgery 
can be performed prior to the MCN developing invasive malig-
nant characteristics. In addition, function-preserving minimally 
invasive surgical approaches would be ideal for a select group of 
patients. Routine medical check-ups and the wider availability 
of axial imaging procedures have contributed to the increasing 
numbers of asymptomatic and smaller MCNs of the pancreas 
being found (1), which is consistent with the results in the present 
study. As the majority of MCNs of the pancreas are located in 
the pancreatic body and tail, minimally invasive pancreatectomy 
is an appropriate surgical approach; this is since laparoscopic 
distal pancreatectomy, with or without splenectomy, is regarded 
as a safe and effective treatment option for benign and borderline 
malignant tumors of the pancreas (25-28).
The perioperative outcomes of a minimally invasive 
approach to MCNs of the pancreas are comparable to those 
of conventional open surgery (Table III). In the present study, 
MIS exhibited a significantly increased duration of surgery 
(316.3±152.1) compared with that of conventional surgery 
(208.3±95.4 min) (P<0.05). However, a difference of 100 min 
may not be clinically significant, considering the fact that 
attempts to achieve spleen-preserving are increasing. When 
considering distal pancreatectomy, which was the most 
frequent surgical procedure performed, it is particularly 
noteworthy that there are several different clinical charac-
teristics between two institutions from different countries. 
These observations may be due to different clinical situ-
ations, such as the individual medical insurance systems 
of the two institutions; however, despite the differences, 
the two institutions dictate the use of a minimally invasive 
approach.
A previous study of 179 MCN cases revealed that a 
large tumor size was associated with an increased risk for 
Table V. Significance of mural nodules in predicting malignant 




Tumor size, cm No Yes P-value
<4.5   1.000
  Mural nodule (-) 22 1 
  Mural nodule (+)   3 0 
≥4.5   0.002
  Mural nodule (-) 21 3 
  Mural nodule (+)   0 5 
Total 46 9 
Table IV. Prediction of malignant transformation of 




Characteristic No Yes P-value
Tumor size <4.5 cm 25 1 0.027
Tumor size ≥4.5 cm 21 8 
Mural nodule (-) 43 4 0.002Mural nodule (+)   3 5 
Total 46 9 
Figure 4. Representative images of a 40-year-old female patient with a 6-cm 
cystic tumor in the distal region of the pancreas. (A) An intracystic solid 
component without invasive characteristics were identified in preoperative 
images [computed tomography (shown), magnetic resonance cholangio-
pancreatography and endoscopic ultrasound]. (B) Laparoscopic 50% distal 
pancreatectomy with splenectomy was performed. Spleen-preservation was 
avoided due to close proximity of the tumor to the splenic hilum and splenic 
vessels. (C) Resected specimen showing a mucinous bloody component with 
intracystic small solitary lesions. (D) Pathological examination (hematoxylin 
and eosin stain; magnification, x400) revealed the resected cystic tumor of 
the pancreas was a borderline mucinous cystic neoplasm. This patient was 
expected to exhibit long-term survival and minimally invasive pancreatec-
tomy was an appropriate approach.
Figure 3. Receiver operating characteristic curve. A tumor size of >4.5 cm was 
identified to predict malignant transformation of mucinous cystic neoplasm 
with an 88.9% sensitivity and a 45.7% false‑positive rate (1‑specificity).
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malignancy (29). As demonstrated in patients with intraductal 
papillary mucin-producing tumors of the pancreas, the cyst 
size of the tumor was associated with malignant transforma-
tion (6,30-32). Typically, a size of 3-4 cm is suggested to be 
a cut-off value for determining the malignant potential of 
MCN of the pancreas (6,12,33). Although there was a limited 
number of cases, the results of the present study demonstrated 
that a tumor size of >4.5 cm was a preoperative parameter 
that may be used to predict the malignant transformation of 
MCN of the pancreas, with 88.9% sensitivity and a 45.7% 
false-positive rate (AUC, 0.719; P=0.039; Fig. 3). In addition, 
it was suggested that preoperative detectable mural nodules 
were a reliable preoperative parameter for the prediction 
malignant transformation in MCN of the pancreas (P=0.002). 
A tumor >4.5 cm combined with an intracystic solid portion 
(mural nodule) were associated with malignant transformation 
(P=0.002; Table V). Yamao et al (24) demonstrated that the 
presence of a large cystic tumor (60,1±38.0 vs. 90.0±45.5 mm, 
P<0.001) and the presence of a nodule (28/129 vs. 14/27, 
P=0.003) were observed at a higher frequency in mucinous 
cystadenocarcinoma compared with that in mucinous cyst 
adenoma. Therefore, it may be appropriate to consider the 
tumor size and the presence of mural nodules together in 
predicting the malignant potential in MCNs of the pancreas.
On the basis of the present study, minimally invasive pancre-
atectomy may be selected for small MCNs (<4.5 cm) without 
an invasive component in preoperative imaging studies. The 
minimally invasive approach may additionally be considered 
for radical pancreatectomy in selected cases (34-37). According 
to the technique and experience of the surgeon involved, 
active minimally invasive pancreatectomy can be applied in 
non-invasive MCN of the pancreas regardless of tumor size. 
If there are no definitive invasive characteristics identified 
in preoperative images, even a large tumor (≥4.5 cm) with a 
mural nodule may be a candidate for the minimally invasive 
approach, according to results of the present study (Figs. 4 and 
5). However, the risk of a rupture of the cyst during the laparo-
scopic approach may increase in cases of large MCNs and may 
lead to tumor metastasis. Nakamura et al (38) demonstrated a 
safe surgical technique for laparoscopic distal pancreatectomy 
involving a large cystic tumor based on securing sufficient 
working space and minimizing intraperitoneal cystic fluid 
spillage. Previous studies have suggested a surgical technique 
for spleen-preserving laparoscopic or robotic subtotal pancre-
atectomy with segmental resection of whole splenic vessels 
to avoid cystic rupture during dissection (39,40). Therefore, 
patient selection and the surgical approach are important.
In summary, pancreatic cystic tumors are a heterogeneous 
disease. However, unique clinical presentations and advanced 
radiological experience can reveal an appropriate preoperative 
diagnosis of MCNs of the pancreas. A tumor size of >4.5 cm 
with the presence of a mural nodule may predict the malignant 
Figure 5. Strategy to MCN of the pancreas based on bi-institutional surgical experiences. According to experiences of surgeons at the two institutions, an 
active minimally invasive approach to MCN of the pancreas is recommended, as non-invasive pancreatic MCN is not aggressive. Minimally invasive radical 
pancreatectomy may be considered even in select cases. Asterisk indicates radical open surgery, open pancreatectomy with lymph node dissection. MCN, 
mucinous cystic neoplasm.
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change of pancreatic MCNs. However, the majority of cystic 
tumors of the pancreas with well‑defined boundaries of cystic 
walls without local invasion in preoperative imaging are 
considered to be benign or borderline MCNs with or without 
focal non-invasive carcinomatous transformation. Therefore, 
minimally invasive and function-preserving pancreatectomy 
may be initially recommended.
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